Lineage Cell Therapeutics In (LCTX) Held by Superinvestors
LINEAGE CELL THERAPEUTICS IN (LCTX) is currently held by 1 superinvestors tracked by InsiderSet, with a combined reported market value of approximately $1.76M based on the latest available SEC Form 13F filings for the quarter ended June 30, 2026.
Renaissance Technologies LLC is currently the largest disclosed institutional shareholder of LCTX tracked by InsiderSet, reporting ownership valued at approximately $1.76M in its June 30, 2026 SEC Form 13F filing. Based on current market prices and the latest disclosed share count, the position is now estimated to be worth approximately $1.34M, representing an estimated loss of -23.66% since the filing period.
The top 10 institutional shareholders tracked on this page collectively account for approximately 100% of the total disclosed LCTX value among the investors covered in this analysis. Major shareholders include Renaissance Technologies LLC, and several other long-term asset managers with concentrated positions in LINEAGE CELL THERAPEUTICS IN (LCTX).
This page ranks the largest institutional LCTX shareholders using publicly disclosed SEC Form 13F data, including reported values, estimated current holding values, portfolio allocation percentages, ownership concentration metrics, and historical holding changes across major hedge funds and investment firms.
| Name | Investor/Manager | Portfolio % | Quantity | Reported Balance | Current Estimated Value | Gain/loss Since Filing | Estimated Portfolio Performance |
|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | Jim Simons | 0.00% | 1,344,829 | $1,761,726 | $1,344,829 | -$416,897 | -23.66% |
Frequently asked questions about LCTX
Who are the largest superinvestors holding LCTX?
The largest superinvestors holding LCTX in the latest SEC Form 13F filings include Renaissance Technologies LLC. InsiderSet ranks these superinvestors by their latest reported LCTX position.
What does the LCTX superinvestors page include?
This page tracks LCTX positions reported by a curated group of notable institutional investors and fund managers through SEC Form 13F. LINEAGE CELL THERAPEUTICS IN (LCTX) on this page reflects disclosed 13F holdings among those superinvestors, not every institutional shareholder of the stock.
How many superinvestors hold LCTX?
InsiderSet currently tracks 1 superinvestors reporting LCTX holdings in the latest available 13F data. This is the curated set on this page, not the total number of institutions that own LCTX.
How much LCTX stock do superinvestors hold?
Superinvestors tracked by InsiderSet disclosed approximately $1.76M in LCTX holdings for Q2 2026. This figure is reported 13F value as of the filing period, not necessarily today's market value, and it covers the curated superinvestors on this page rather than every institutional filer.
When were LCTX superinvestor holdings last updated?
The latest LCTX superinvestor holdings on InsiderSet are based on SEC Form 13F filings for the quarter ended June 30, 2026. Form 13F filings are generally reported after the quarter ends, so the holdings shown represent the latest publicly disclosed positions rather than real-time holdings.
Are superinvestor LCTX holdings real-time?
No. Form 13F data is not real-time. It represents positions reported by these superinvestors as of the end of the reporting quarter. A superinvestor may have changed its LCTX position after the reporting date.
Are superinvestors buying or selling LCTX?
Buying and selling can be analyzed by comparing LCTX positions across consecutive 13F reporting periods. InsiderSet's LCTX Ownership Changes page shows institutions that increased, reduced, initiated, or exited positions based on reported 13F holdings. View LCTX ownership changes.
How have superinvestor LCTX holdings changed over time?
InsiderSet tracks LCTX holdings among these superinvestors across multiple 13F reporting periods, so holder counts, reported value, and reported shares can be compared over time.